29 July 2024
INTERIM RESULTS ANNOUNCEMENT Results for the six months ended 30 June 2024 The full Interim Report for the six months ended 30 June 2024…
Fixed-duration Calquence plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukaemia in AMPLIFY Phase III trial Favourable trend in overall survival…
29 July 2024 Dotdigital Group plc (“Dotdigital”, the “Company”, or the “Group”) Trading Update A year of financial and strategic progress Dotdigital Group plc (AIM: DOTD),…
Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) announces: Key Highlights Revenue €17,823 millionNet revenue (beia) 6.0% organic growth; per hectolitre 4.3%Beer volume organic growth 2.1%; Heineken®…
29 July 2024 Watkin Jones plc (‘Watkin Jones’ or the ‘Group’) Major PBSA development funded with HGP Watkin Jones, the UK’s leading developer and…
26 July 2024
Continued Rental Growth, Valuations Stabilised SEGRO plc’s Half Year 2024 Results have been submitted in full unedited text to the Financial Conduct Authority’s National…
Euronext’s diversified business model continues to drive strong topline growth. Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 25 July 2024 – Euronext, the leading…
FDA Advisory Committee reviewed Imfinzi for treatment of resectable non-small cell lung cancer based on AEGEAN Phase III trial results The Food and Drug Administration’s (FDA)…